ISSN: 1837-9664Journal of Cancer
Global reach, higher impact
J Cancer 2024; 15(8):2373-2379. doi:10.7150/jca.93733 This issue Cite
Research Paper
CMTM6: A Critical Prognostic Indicator in Non-Small Cell Lung Cancer
1. College of Chemistry and Environmental Science, Qujing Normal University, Qujing, Yunnan, 655011, China.
2. Graduate School, Kunming Medical University, Kunming, Yunnan, China.
3. 920th Hospital of the Joint Logistics Support Force of PLA, Kunming, Yunnan, China.
4. College of Biological Resource and Food Engineering, Qujing Normal University, Qujing, Yunnan, 655011, China.
Abstract
While CKLF-like MARVEL transmembrane domain containing 6 (CMTM6)'s role in stabilizing PD-L1 and immune evasion within tumors is established, its expression in lung cancer tissue and adjacent macrophages remains uncertain. The study aimed to elucidate this ambiguity by investigating CMTM6's role in non-small cell lung cancer (NSCLC) prognosis. Employing immunohistochemical staining on 141 NSCLC and 110 adjacent normal lung tissue samples, CMTM6 expression was evaluated using the HSCORE system. Interestingly, NSCLC exhibited significantly higher CMTM6 levels (161.04±86.60) compared to normal tissues (71.20±45.10) (p < 0.001), detected not only in cancer cells but also in macrophages, lymphocytes, and nearby bronchial epithelial cells. Stratifying patients by CMTM6 levels unveiled a correlation between heightened expression and poorer overall survival (p = 0.003), alongside a link to tumor-infiltrating lymphocytes (TIL) (p = 0.037), especially in cases with increased TIL. Multivariate analysis identified CMTM6 as an independent predictor of overall survival (p = 0.009), implying that elevated CMTM6 expression in NSCLC might signify an adverse prognostic marker for patient outcomes.
Keywords: CMTM6, prognosis, NSCLC, immunohistochemical
Citation styles
